Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04272333 · ClinicalTrials.gov registry record · Early Phase 1
Intratumoral Microdosing of Motolimod in HNSCC
A Early Phase 1 study, sponsored by Presage Biosciences.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 1
- Enrollment target
NCT04272333 is a Early Phase 1 study that was terminated before completion, run by Presage Biosciences. The registered enrollment target is 1 participants.
The verdict
NCT04272333, a Early Phase 1 study, was terminated before completion, sponsored by Presage Biosciences.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
This is a multi-center, single arm, open-label, multi-agent, localized pharmacodynamic biomarker Phase 0 trial designed to study the biological effects within the tumor microenvironment of motolimod and motolimod combined with nivolumab when administered intratumorally in microdose quantities via the CIVO device in patients with head and neck squamous cell carcinoma (HNSCC). CIVO stands for comparative in vivo oncology.
Interventions
- BIOLOGICAL Nivolumab
- DRUG Motolimod
- COMBINATION_PRODUCT Motolimod + Nivolumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2021-10-15 |
| Est. Completion | 2022-03-25 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04272333
The ClinicalTrials.gov registry entry for NCT04272333 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Presage Biosciences, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Nivolumab is the first listed.
NCT04272333 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04272333 about?
NCT04272333 is a clinical study titled "Intratumoral Microdosing of Motolimod in HNSCC". This is a multi-center, single arm, open-label, multi-agent, localized pharmacodynamic biomarker Phase 0 trial designed to study the biological effects within the tumor microenvironment of motolimod and motolimod combined with nivolumab when administered intratumorally in microdose quantities via th...
What is the current status of trial NCT04272333?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 1 participants. The study started on 2021-10-15. Estimated completion is 2022-03-25.
What interventions are being tested in trial NCT04272333?
The interventions under investigation include: Nivolumab (BIOLOGICAL), Motolimod (DRUG), Motolimod + Nivolumab (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT04272333?
This trial is sponsored by Presage Biosciences, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.